A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C

Iannazzo, Sergio; Colombatto, P.; Ricco, G.; Oliveri, Filippo; Bonino, Ferruccio; Brunetto, Maurizia Rossana

doi:10.1016/j.dld.2014.12.008

Cited by 5 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If adequately designed, early detection strategies might ensure prompt treatment of infected patients and allow better targeting of the new effective, but also costly, medical treatments as suggested by recent studies investigating the cost-effectiveness of the new molecules. 12 , 13 This would ultimately reduce the occurrence of chronicity-related complications with a twofold positive impact on both patients’ health and health care expenditure.…”

Section: Introductionmentioning

confidence: 99%

Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature

Coretti

Romano

Orlando

et al. 2015

RMHP

View full text Add to dashboard Cite

BackgroundHepatitis C is a liver infection caused by hepatitis C virus. Its main complications are cirrhosis and liver cancer. According to the World Health Organization (WHO), more than 185 million people worldwide are infected with hepatitis C virus and, of these, 350,000 die every year. Due to the high disease prevalence and the existence of effective (and expensive) medical treatments able to dramatically change the prognosis, early detection programs can potentially prevent the development of serious chronic conditions, improve health, and save resources.ObjectiveTo summarize the available evidence on the cost-effectiveness of screening programs for hepatitis C.MethodsA literature search was performed on PubMed and Scopus search engines. Trip database was queried to identify reports produced by the major Health Technology Assessment (HTA) agencies. Three reviewers dealt with study selection and data extraction blindly.ResultsTen papers eventually met the inclusion criteria. In studies focusing on asymptomatic cohorts of individuals at general risk the cost/quality adjusted life year of screening programs ranged between US $4,200 and $50,000/quality adjusted life year gained, while in those focusing on specific risk factors the incremental cost-effectiveness ratio ranged between $848 and $128,424/quality adjusted life year gained. Age of the target population and disease prevalence were the main cost-effectiveness drivers.ConclusionOur results suggest that, especially in the long run, screening programs represent a cost-effective strategy for the management of hepatitis C.

show abstract

Section: Introductionmentioning

confidence: 99%

Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature

Coretti

Romano

Orlando

et al. 2015

RMHP

View full text Add to dashboard Cite

show abstract

Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy

Colombatto

Bonino

Civitano

et al. 2016

Hepatitis C Virus II

View full text Add to dashboard Cite

Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

Leidner

Chesson

Spradling

et al. 2016

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background Most cost-effectiveness analyses of hepatitis C (HCV) therapy focus on the benefits of reducing liver-related morbidity and mortality. Objectives Our objective was to assess how cost-effectiveness estimates of HCV therapy can vary depending on assumptions regarding the potential impact of HCV therapy on non-hepatic mortality. Methods We adapted a state-transition model to include potential effects of HCV therapy on non-hepatic mortality. We assumed successful treatment could reduce non-hepatic mortality by as little as 0 % to as much as 100 %. Incremental cost-effectiveness ratios were computed comparing immediate treatment versus delayed treatment and comparing immediate treatment versus non-treatment. Results Comparing immediate treatment versus delayed treatment, when we included a 44 % reduction in nonhepatic mortality following successful HCV treatment, the incremental cost per quality-adjusted life year (QALY) gained by HCV treatment fell by 76 % (from US$314,100 to US$76,900) for patients with no fibrosis and by 43 % (from US$62,500 to US$35,800) for patients with moderate fibrosis. Comparing immediate treatment versus non-treatment, assuming a 44 % reduction in non-hepatic mortality following successful HCV treatment, the incremental cost per QALY gained by HCV treatment fell by 64 % (from US$186,700 to US$67,300) for patients with no fibrosis and by 27 % (from US$35,000 to US$25,500) for patients with moderate fibrosis. Conclusion Including reductions in non-hepatic mortality from HCV treatment can have substantial effects on the estimated cost-effectiveness of treatment.

show abstract

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C

Cited by 5 publications

References 22 publications

Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature

Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature

Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy

Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

Contact Info

Product

Resources

About